Literature DB >> 32124504

Imaging quality of PROPELLER diffusion-weighted MR imaging and its diagnostic performance in distinguishing pleomorphic adenomas from Warthin tumors of the parotid gland.

Yi-Jui Liu1, Yi-Hsiung Lee2,3, Hing-Chiu Chang4, Hsiao-Wen Chung5, Chih-Wei Wang3, Cheng-Hsuan Juan1, Yueng-Hsiang Chu6, Jih-Chin Lee6, Chun-Jung Juan7,8.   

Abstract

The aim of this study was to evaluate the imaging quality and diagnostic performance of fast spin echo diffusion-weighted imaging with periodically rotated overlapping parallel lines with enhanced reconstruction (FSE-PROP-DWI) in distinguishing parotid pleomorphic adenoma (PMA) from Warthin tumor (WT). This retrospective study enrolled 44 parotid gland tumors from 34 patients, including 15 PMAs and 29 WTs with waived written informed consent. All participants underwent 1.5 T diffusion-weighted imaging including FSE-PROP-DWI and single-shot echo-planar diffusion-weighted imaging (SS-EP-DWI). After imaging resizing and registration among T2WI, FSE-PROP-DWI and SS-EP-DWI, imaging distortion was quantitatively analyzed by using the Dice coefficient. Signal-to-noise ratio and contrast-to-noise ratio were qualitatively evaluated. The mean apparent diffusion coefficient (ADC) of parotid gland tumors was calculated. Wilcoxon signed-rank test was used for paired comparison between FSE-PROP-DWI versus SS-EP-DWI. Mann-Whitney U test was used for independent group comparison between PMAs versus WTs. Diagnostic performance was evaluated by receiver operating characteristics curve analysis. P < 0.05 was considered statistically significant. The Dice coefficient was statistically significantly higher on FSE-PROP-DWI than SS-EP-DWI for both tumors (P < 0.005). Mean ADC was statistically significantly higher in PMAs than WTs on both FSE-PROP-DWI and SS-EP-DWI (P < 0.005). FSE-PROP-DWI and SS-EP-DWI successfully distinguished PMAs from WTs with an AUC of 0.880 and 0.945, respectively (P < 0.05). Sensitivity, specificity, positive predictive value, negative predictive value and accuracy in diagnosing PMAs were 100%, 69.0%, 62.5%, 100% and 79.5% for FSE-PROP-DWI, and 100%, 82.8%, 75%, 100% and 88.6% for SS-EP-DWI, respectively. FSE-PROP-DWI is useful to distinguish parotid PMAs from WTs with less distortion of tumors but lower AUC than SS-EP-DWI.
© 2020 John Wiley & Sons, Ltd.

Entities:  

Keywords:  PROPELLER; Warthin tumor; dice coefficient; diffusion-weighted imaging; echo-planar imaging; mean apparent diffusion coefficient; parotid gland; pleomorphic adenoma

Mesh:

Year:  2020        PMID: 32124504     DOI: 10.1002/nbm.4282

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  4 in total

1.  Development and validation of an MRI-based radiomics nomogram for distinguishing Warthin's tumour from pleomorphic adenomas of the parotid gland.

Authors:  Ying-Mei Zheng; Jiao Chen; Qi Xu; Wen-Hui Zhao; Xin-Feng Wang; Ming-Gang Yuan; Zong-Jing Liu; Zeng-Jie Wu; Cheng Dong
Journal:  Dentomaxillofac Radiol       Date:  2021-05-05       Impact factor: 3.525

2.  Differentiation of Benign From Malignant Parotid Gland Tumors Using Conventional MRI Based on Radiomics Nomogram.

Authors:  Jinbo Qi; Ankang Gao; Xiaoyue Ma; Yang Song; Guohua Zhao; Jie Bai; Eryuan Gao; Kai Zhao; Baohong Wen; Yong Zhang; Jingliang Cheng
Journal:  Front Oncol       Date:  2022-07-11       Impact factor: 5.738

3.  Feasibility evaluation of amide proton transfer-weighted imaging in the parotid glands: a strategy to recognize artifacts and measure APT value.

Authors:  Yu Chen; Xiaoqi Wang; Tong Su; Zhentan Xu; Yunting Wang; Zhuhua Zhang; Huadan Xue; Zhizheng Zhuo; Yuanli Zhu; Zhengyu Jin; Tao Zhang
Journal:  Quant Imaging Med Surg       Date:  2021-06

4.  Quantitative Analysis and Pathological Basis of Signal Intensity on T2-Weighted MR Images in Benign and Malignant Parotid Tumors.

Authors:  Peiying Wei; Chang Shao; Min Tian; Mengwei Wu; Haibin Wang; Zhijiang Han; Hongjie Hu
Journal:  Cancer Manag Res       Date:  2021-07-07       Impact factor: 3.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.